Quantum Sniffer(TM) QS-B220 Explosives and Narcotics Trace Detector Selected for TSL Technology Optimization Partnership
WILMINGTON, MA, Nov 02, 2011 (MARKETWIRE via COMTEX) --
Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a
high technology supplier of systems and sensors for homeland security
markets, today announced that its Quantum Sniffer(TM) QS-B220
benchtop explosives trace detector has been approved to partner with
the developmental test and evaluation group of the Transportation
Security Laboratory (TSL) in order to optimize the QS-B220 detection
technology. TSL is a Department of Homeland Security Federal
Laboratory within the DHS Science and Technology Directorate (S&T),
located at the William J. Hughes Technical Center, Atlantic City
International Airport, New Jersey.
Implant Sciences has signed a Cooperative Research and Development
Agreement (CRADA) with DHS S&T TSL to officially begin its technology
DHS S&T/TSL's core mission is to enhance homeland security, including
the research, development and validation of solutions to detect and
mitigate the threat of improvised explosive devices (IEDs). DHS S&T
establishes CRADAs as public-private partnerships designed to
expeditiously mature and deploy security technologies and to prepare
products to achieve Transportation Security Administration (TSA)
certification/qualification. TSA certified products may be used at
ports of entry across the U.S., including airports.
Implant Sciences' Vice President of Technology, Todd Silvestri
stated, "The insight of the professionals at TSL will be invaluable
in preparing the QS-B220 to meet TSA's expectations. TSL brings
extensive experience and expertise to the table which will help us
build a better product."
"We are proud to be able to work with S&T to optimize our technology.
This is a great example of a private-public partnership that helps
save money for taxpayers while improving security in the United
States," concluded Implant Sciences' President and CEO, Glenn D.
About the Quantum Sniffer QS-B220
The QS-B220 Quantum Sniffer, introduced in May 2011, is a benchtop
explosives and narcotics trace detector that uses Ion Mobility
Spectrometry (IMS) to rapidly detect and identify trace amounts of a
wide variety of military, commercial, improvised, or homemade
explosives and narcotic substances. The QS-B220 continues the Implant
Sciences tradition of freedom from radioactive materials, low total
cost of ownership, and high operational availability. The QS-B220
benchtop explosives and narcotics trace detector has received a
Developmental Testing & Evaluation (DT&E) Designation by the U.S.
Department of Homeland Security under the Support Anti-terrorism by
Fostering Effective Technology Act of 2002 (the SAFETY Act).
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated
sensors and systems for Security, Safety, and Defense (SS&D) markets.
The Company has developed proprietary technologies used in its
commercial explosive trace detection systems which ship to a growing
number of locations domestically and internationally. The QS-H150 and
QS-B220 are Department of Homeland Security (DHS) Qualified
Anti-Terrorism Technologies under the Support Anti-terrorism by
Fostering Effective Technology Act of 2002 (the SAFETY Act). For
further details on the Company and its products, please visit the
Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements,"
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Such statements are based on management's current
expectations and are subject to risks and uncertainties that could
cause the Company's actual results to differ materially from the
forward-looking statements. Such risks and uncertainties include, but
are not limited to, the risks that our explosives detection products
and technologies (including any new products we may develop) may not
be accepted by U.S. or foreign governments or by other law
enforcement agencies or commercial consumers of security products;
economic, political and other risks associated with international
sales and operations could adversely affect our sales; our business
is subject to intense competition and rapid technological change;
liability claims related to our products or our handling of hazardous
materials could damage our reputation and have a material adverse
effect on our financial results; and other risks and uncertainties
described in our filings with the Securities and Exchange Commission,
including our most recent Forms 10-K, 10-Q and 8-K. Such statements
are based on management's current expectations and assumptions which
could differ materially from the forward-looking statements.
Implant Sciences Corporation
SOURCE: Implant Sciences